Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect

References

• Doktorovova S, Souto EB, Silva AM. (2014). Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur J Pharm Biopharm 87:1–18
   PubMed Web of Science ®Google Scholar
• Duan Y, Wang J, Yang X, et al. (2015). Curcumin-loaded mixed micelles: preparation, optimization, physicochemical properties and cytotoxicity in vitro. Drug Deliv 22:50–7
   PubMed Web of Science ®Google Scholar
• Feng T, Tian H, Xu C, et al. (2014). Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm 88:1086–93
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, et al. (2012). Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 20:813–30
   PubMed Web of Science ®Google Scholar
• Langer CJ, Novello S, Park K, et al. (2014). Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 32:2059–66
   PubMed Web of Science ®Google Scholar
• Li M, Liu P, Gao G, et al. (2015). Smac therapeutic Peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with Doxorubicin. ACS Appl Mater Interfaces 7:8005–12
   PubMed Web of Science ®Google Scholar
• Lin T, Fang Q, Peng D, et al. (2013). PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid. Drug Deliv 20:277–84
   PubMed Web of Science ®Google Scholar
• Lv S, Tang Z, Li M, et al. (2014). Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35:6118–29
   PubMed Web of Science ®Google Scholar
• Ma P, Mumper RJ. (2013). Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 4:1000164
   PubMedGoogle Scholar
• Moreno-Aspitia A, Perez EA. (2009). Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31:1619–40
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Karatgi P, Paruchuri S, et al. (2011). Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration. Drug Deliv 18:294–303
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. (2008). Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:1980–6
   PubMed Web of Science ®Google Scholar
• Rahman HS, Rasedee A, How CW, et al. (2013). Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomedicine 8:2769–81
   PubMed Web of Science ®Google Scholar
• Rivankar S. (2014). An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 10:853–8
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Ansari R, Walker P, et al. (2000). Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 23:68–70
   PubMed Web of Science ®Google Scholar
• Su CW, Chiang CS, Li WM, et al. (2014). Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment. Nanomedicine (Lond) 9:1499–515
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, et al. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349–57
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao Y, Wu Y, et al. (2011). Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32:8281–90
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma S, Xie Z, et al. (2014). A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Colloids Surf B Biointerfaces 116:41–8
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Tardi PG, Mayer LD, et al. (2001). A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24:903–20
   PubMedGoogle Scholar
• Weber S, Zimmer A, Pardeike J. (2014). Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 86:7–22
   PubMed Web of Science ®Google Scholar
• Yadav AK, Agarwal A, Rai G, et al. (2010). Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv 17:561–72
   PubMed Web of Science ®Google Scholar
• Yuan L, Liu C, Chen Y, et al. (2013). Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model. Int J Nanomedicine 8:4339–50
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Wang XP, Ayman WY, et al. (2013). Studies on lactoferrin nanoparticles of gambogic acid for oral delivery. Drug Deliv 20:86–93
   PubMed Web of Science ®Google Scholar
• Zhao Y, Alakhova DY, Kabanov AV. (2013). Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 65:1763–83
   PubMed Web of Science ®Google Scholar